Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 16/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | PPM1D | O15297 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3005069 | 1.00 | REN (0.42) | RENCYP3A4CTSSPPM1DCTSL | |
| SCHEMBL3000136 | 0.94 | REN (0.38) | RENCYP3A4CTSSPPM1DMETAP2 | |
| SCHEMBL3000140 | 0.94 | REN (0.38) | RENCYP3A4CTSSPPM1DMETAP2 | |
| SCHEMBL3004685 | 0.91 | CHRNB2 (0.38) | RENCYP3A4CTSSPPM1DCTSL | |
| SCHEMBL3004682 | 0.91 | CHRNB2 (0.38) | RENCYP3A4CTSSPPM1DCTSL | |
| SCHEMBL3004738 | 0.85 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL2998864 | 0.85 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL1866530 | 0.80 | CTSL (0.39) | CTSSPPM1DCTSLCTSK | |
| SCHEMBL1866531 | 0.80 | CTSL (0.39) | CTSSPPM1DCTSLCTSK | |
| SCHEMBL1861541 | 0.80 | CTSL (0.39) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190829-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190829-A1 | RENIN INHIBITORS | ACE, REN, DNPEP | REN 2/4885CYP3A4 3133/4885CTSS 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.